ClinicalTrials.gg
CompletedNCT05557409ADVANCE-2Updated Aug 13, 2026Results posted

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation

A Phase 3 interventional study of AXS-05 and Placebo in Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease and Agitation, sponsored by Axsome Therapeutics, Inc.. Completed at 55 sites in 2 countries. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
65 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
229th of 1,609
408 · median 73
Started
2022
with 130 others
Phase 3
188 of 1,940
19 open now
Registered
1,510th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 229th largest by enrollment of the 1,609 interventional ones that give a count, is one of 131 that started in 2022, is one of 188 in phase 3, and was the 1,510th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 65 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This trial was a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.

Read the detailed description

Eligible subjects were randomized in a 1:1 ratio for up to 5 weeks to be treated with AXS-05 or placebo.

03

Conditions studied

  • Agitation in Patients With Dementia of the Alzheimer's Type
  • Alzheimer Disease
  • Agitation

Keywords

  • AD agitation
  • AXS-05
  • NMDA receptor antagonist
  • dextromethorphan
  • bupropion
  • Axsome
  • ADVANCE-2
04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria.
  • Diagnosis of agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation.

Exclusion criteria

Exclusion Criteria:

  • Patient has dementia predominantly of non-Alzheimer's type.
  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
408 participants (actual)

Study arms

  • Experimental
    AXS-05

    Up to 5 weeks

    Drug: AXS-05

  • Placebo comparator
    Placebo

    Up to 5 weeks

    Drug: Placebo

Interventions

  • DrugAXS-05

    AXS-05 tablets, taken twice daily

  • DrugPlacebo

    Placebo tablets, taken twice daily

06

What researchers measure

Primary outcomes

  1. Cohen-Mansfield Agitation Inventory (CMAI)

    The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver-rated questionnaire that assesses the frequency of agitation-related and disruptive behaviors in subjects with dementia. The scale contains 29 behaviors or items organized into four subscales: physically aggressive, physically non-aggressive, verbally aggressive, and verbally non-aggressive. The CMAI is administered by interviewing the caregiver and asking him or her to rate the frequency with which the subject manifests each behavior using a seven-point scale: 1=never (better outcome), 7=several times an hour (worse outcome). The CMAI total score is the sum of the scores for all of the items in the CMAI. CMAI total scores range from a minimum of 29 (better outcome) to a maximum of 203 (worse outcome).

    Time frame: Up to 5 weeks

07

Results

Posted Aug 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneAXS-05Placebo
Started204204
Completed194194
Not completed1010

Outcome measures

PrimaryCohen-Mansfield Agitation Inventory (CMAI)

The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver-rated questionnaire that assesses the frequency of agitation-related and disruptive behaviors in subjects with dementia. The scale contains 29 behaviors or items organized into four subscales: physically aggressive, physically non-aggressive, verbally aggressive, and verbally non-aggressive. The CMAI is administered by interviewing the caregiver and asking him or her to rate the frequency with which the subject manifests each behavior using a seven-point scale: 1=never (better outcome), 7=several times an hour (worse outcome). The CMAI total score is the sum of the scores for all of the items in the CMAI. CMAI total scores range from a minimum of 29 (better outcome) to a maximum of 203 (worse outcome).

Time frame:
Up to 5 weeks
Reported as:
Least squares mean · score on a scale
Cohen-Mansfield Agitation Inventory (CMAI)
score on a scaleAXS-05Placebo
Cohen-Mansfield Agitation Inventory (CMAI)-13.85 ± 0.917-12.77 ± 0.921
Statistical analysis
  • AXS-05 vs Placebo · Mixed Models Analysis · p = 0.407

Adverse events

Collected over Treatment emergent adverse events (TEAEs) were collected after administration of study drug through 7 days after the last dose (up to 5 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AXS-050/204 (0%)2/204 (1%)27/204 (13.2%)
Placebo0/204 (0%)0/204 (0%)15/204 (7.4%)
Most frequent serious events
Most frequent serious events
EventAXS-05Placebo
Urinary tract infectionInfections and infestations1/2040/204
AstheniaGeneral disorders1/2040/204
Cerebrovascular accidentNervous system disorders1/2040/204
Most frequent other events
Most frequent other events
EventAXS-05Placebo
DizzinessNervous system disorders12/2043/204
HeadacheNervous system disorders9/2047/204
SomnolenceNervous system disorders6/2045/204

Baseline characteristics

Age, Continuous
Age, Continuous(years)AXS-05PlaceboTotal
Mean73.6 ± 5.3475.0 ± 5.7474.3 ± 5.58
Sex: Female, Male
Sex: Female, Male(Participants)AXS-05PlaceboTotal
Female130112242
Male7492166
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)AXS-05PlaceboTotal
Black or African American182341
Asian224
White184178362
Other011
08

Study locations

55 sites
  • Clinical Research Site
    Peoria, Arizona 85381, United States
  • Clinical Research Site
    Tempe, Arizona 85282, United States
  • Clinical Research Site
    Tucson, Arizona 85710, United States
  • Clinical Research Site
    Canoga Park, California 91303, United States
  • Clinical Research Site
    Long Beach, California 90807, United States
  • Clinical Research Site
    Los Alamitos, California 90720, United States
  • Clinical Research Site
    Walnut Creek, California 94596, United States
  • Clinical Research Site
    West Covina, California 91790, United States
  • Clinical Research Site
    Bonita Springs, Florida 34134, United States
  • Clinical Research Site
    Brandon, Florida 33511, United States
  • Clinical Research Site
    Green Acres, Florida 33467, United States
  • Clinical Research Site
    Hialeah, Florida 33012, United States
  • Clinical Research Site
    Hollywood, Florida 33024, United States
  • Clinical Research Site
    Kissimmee, Florida 34741, United States
  • Clinical Research Site
    Miami, Florida 33126, United States
  • Clinical Research Site
    Miami, Florida 33135, United States
  • Clinical Research Site
    Miami, Florida 33145, United States
  • Clinical Research Site
    Miami, Florida 33155, United States
  • Clinical Research Site
    Miami, Florida 33165, United States
  • Clinical Research Site
    Miami, Florida 33173, United States
  • Clinical Research Site
    Miami, Florida 33175, United States
  • Clinical Research Site
    Miami Gardens, Florida 33014, United States
  • Clinical Research Site
    Miami Lakes, Florida 33014, United States
  • Clinical Research Site
    Orlando, Florida 32807, United States
  • Clinical Research Site
    Pembroke Pines, Florida 33025, United States
  • Clinical Research Site
    Tampa, Florida 33614, United States
  • Clinical Research Site
    Tampa, Florida 33634, United States
  • Clinical Research Site
    Augusta, Georgia 30912, United States
  • Clinical Research Site
    College Park, Georgia 30349, United States
  • Clinical Research Site
    Columbus, Georgia 31909, United States
  • Clinical Research Site
    Wichita, Kansas 67214, United States
  • Clinical Research Site
    Marrero, Louisiana 70072, United States
  • Clinical Research Site
    Braintree, Massachusetts 02184, United States
  • Clinical Research Site
    Flint, Michigan 48532, United States
  • Clinical Research Site
    Rochester Hills, Michigan 48307, United States
  • Clinical Research Site
    Troy, Michigan 48085, United States
  • Clinical Research Site
    Chesterfield, Missouri 63005, United States
  • Clinical Research Site
    Berlin, New Jersey 08009, United States
  • Clinical Research Site
    Toms River, New Jersey 08755, United States
  • Clinical Research Site
    Brooklyn, New York 11229, United States
  • Clinical Research Site
    New Windsor, New York 12553, United States
  • Clinical Research Site
    Staten Island, New York 10314, United States
  • Clinical Research Site
    Woodmere, New York 11598, United States
  • Clinical Research Site
    Charlotte, North Carolina 28211, United States
  • Clinical Research Site
    Hickory, North Carolina 28601, United States
  • Clinical Research Site
    Middleburg Heights, Ohio 44130, United States
  • Clinical Research Site
    Austin, Texas 78737, United States
  • Clinical Research Site
    Cypress, Texas 77429, United States
  • Clinical Research Site
    Mesquite, Texas 75149, United States
  • Clinical Research Site
    San Antonio, Texas 78229, United States
  • Clinical Research Site
    Sugarland, Texas 77478, United States
  • Clinical Research Site
    Rutland, Vermont 05701, United States
  • Clinical Research Site
    Arlington, Virginia 22205, United States
  • Clinical Research Site
    Bayamón, Puerto Rico 00961, Puerto Rico
  • Clinical Research Site
    San Juan, Puerto Rico 00918, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Nov 2024, 26 months.

Results were first posted in Aug 2026, 1 year 8 months after primary completion. A results delay was requested in Nov 2025.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 26 months is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2022
First posted
Sep 28, 2022
StartActual
Sep 6, 2022
Primary completionActual
Nov 21, 2024
CompletionActual
Dec 21, 2024
Results delay requested
Nov 20, 2025
Results first posted
Aug 13, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05557409
Responsible party
Sponsor
First posted
Sep 28, 2022
Start date
Sep 6, 2022
Primary completion
Nov 21, 2024
Completion
Dec 21, 2024
Results posted
Aug 13, 2026
Last update
Aug 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05

Start the discussion